OFI Invest Asset Management Has $90.06 Million Stock Position in Intuitive Surgical, Inc. $ISRG

OFI Invest Asset Management boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 28.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 159,009 shares of the medical equipment provider’s stock after buying an additional 34,933 shares during the period. Intuitive Surgical makes up approximately 1.1% of OFI Invest Asset Management’s holdings, making the stock its 15th biggest holding. OFI Invest Asset Management’s holdings in Intuitive Surgical were worth $90,056,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ISRG. Brighton Jones LLC raised its holdings in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after buying an additional 731 shares during the period. Sivia Capital Partners LLC raised its holdings in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after buying an additional 34 shares during the period. Schnieders Capital Management LLC. raised its holdings in Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after buying an additional 268 shares during the period. iSAM Funds UK Ltd acquired a new stake in Intuitive Surgical during the 2nd quarter worth approximately $293,000. Finally, Stamos Capital Partners L.P. raised its holdings in Intuitive Surgical by 82.2% during the 2nd quarter. Stamos Capital Partners L.P. now owns 1,811 shares of the medical equipment provider’s stock worth $984,000 after buying an additional 817 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. UBS Group decreased their price target on shares of Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Argus decreased their price target on shares of Intuitive Surgical from $630.00 to $560.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Royal Bank Of Canada raised their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, Citigroup raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price target for the company in a research note on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $607.00.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Gary S. Guthart sold 24,500 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the transaction, the director directly owned 3,694 shares in the company, valued at approximately $1,958,189.40. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 421 shares of the business’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total transaction of $208,378.16. Following the transaction, the executive vice president owned 409 shares in the company, valued at approximately $202,438.64. The trade was a 50.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,943 shares of company stock valued at $17,279,568 in the last 90 days. Company insiders own 0.60% of the company’s stock.

More Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive’s push to embed AI into its da Vinci systems reinforces the company’s long‑term growth and margin story, supporting investor confidence in recurring procedure growth and software monetization. AI Push Article
• Positive Sentiment: Goldman Sachs kept a Buy rating on ISRG, signaling continued institutional support despite lowering its price target to $609 — the maintained Buy reduces downside risk for some investors. Goldman Sachs PT Article
• Positive Sentiment: Third‑party coverage highlights Intuitive’s strong balance sheet (no debt) and near‑monopoly position in robotic surgery — a supportive fundamental narrative for long‑term investors. Fool No‑Debt Article
• Positive Sentiment: Analysts and commentators point to an underappreciated large opportunity in anti‑obesity procedures that could widen Intuitive’s TAM and future procedure volumes. Anti‑Obesity Opportunity Article
• Neutral Sentiment: Market summaries note ISRG rose today but underperformed the market, suggesting selective buying rather than broad momentum. Zacks Market Summary
• Neutral Sentiment: Erste Group trimmed FY2027 EPS estimates very slightly (from $9.54 to $9.52) — the change is immaterial to near‑term outlook but reflects close monitoring of margins and procedure growth.
• Negative Sentiment: Evercore published a pessimistic forecast for ISRG, introducing downside bias from a well‑known sell‑side voice that can influence short‑term flows and sentiment. Evercore Forecast Article
• Negative Sentiment: Goldman’s sizable cut to its price target (from $714 to $609) signals valuation pressure — even with a Buy rating, lower targets can prompt profit‑taking or cap repositioning by funds. Goldman Sachs PT Article

Intuitive Surgical Stock Up 2.1%

Shares of ISRG opened at $462.28 on Thursday. The stock has a market capitalization of $164.17 billion, a P/E ratio of 58.59, a P/E/G ratio of 3.49 and a beta of 1.68. Intuitive Surgical, Inc. has a twelve month low of $427.84 and a twelve month high of $603.88. The company has a 50 day moving average of $483.27 and a 200-day moving average of $514.06.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. The business had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm’s revenue was up 18.8% on a year-over-year basis. During the same period last year, the business earned $2.21 earnings per share. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.